Literature DB >> 16185907

Gaucher disease in Colombia: mutation identification and comparison to other Hispanic populations.

R J Pomponio1, M A Cabrera-Salazar, O Y Echeverri, G Miller, L A Barrera.   

Abstract

Gaucher disease is the most common of the lysosomal storage disorders, affecting all ethnic groups. The pathology of this recessively inherited disease arises from the accumulation of glucocerebroside in tissues due to deficient activity of the enzyme glucocerebrosidase (E.C. 3.2.1.45). The glucocerebrosidase (GBA) gene spans a 7.2kb fragment located on locus 1q 21, consisting of 11 exons and 10 introns. Located 16 kb downstream is a highly homologous pseudogene sequence [M. Horowitz, S. Wilder, Z. Horowitz, O. Reiner, T. Gelbart, E. Beutler, The Human Glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4 (1) (1989) 87-96.]. Fourteen fragments comprising 11 exons of the GBA gene were analyzed in DNA samples from 25 Colombian patients using denaturing High Pressure Liquid Chromatography (DHPLC). Sequencing of abnormal findings led to the discovery of three novel mutations (c.595_596 delCT, c.898 delG and c.1,255 G>C [p.D 419 H] in exons 6, 7, and 9 of the GBA gene) with high prevalence among Colombian patients. We have also found the presence of a double mutation p.L 483 P+p.E 355 K (L 444 P+E 326 K, traditional nomenclature) in two different families classified as Gaucher type 1. This mutation was previously reported in one patient with Gaucher type 2. We have found DHPLC to be a reliable and sensitive method for the detection of mutations and allelic variation in Gaucher patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185907     DOI: 10.1016/j.ymgme.2005.07.026

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  4 in total

1.  A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

Authors:  Elena Lukina; Nora Watman; Elsa Avila Arreguin; Maryam Banikazemi; Marta Dragosky; Marcelo Iastrebner; Hanna Rosenbaum; Mici Phillips; Gregory M Pastores; Daniel I Rosenthal; Mathilde Kaper; Tejdip Singh; Ana Cristina Puga; Peter L Bonate; M Judith Peterschmitt
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

2.  The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru.

Authors:  Carlos Velez-Pardo; Oswaldo Lorenzo-Betancor; Marlene Jimenez-Del-Rio; Sonia Moreno; Francisco Lopera; Mario Cornejo-Olivas; Luis Torres; Miguel Inca-Martinez; Pilar Mazzetti; Carlos Cosentino; Dora Yearout; Sarah M Waldherr; Cyrus P Zabetian; Ignacio F Mata
Journal:  Parkinsonism Relat Disord       Date:  2019-02-04       Impact factor: 4.891

3.  Gaucher disease in Syrian children: common mutations identification, and clinical futures.

Authors:  Diana Alasmar
Journal:  Ann Saudi Med       Date:  2015 Mar-Apr       Impact factor: 1.526

4.  Analysis of glucocerebrosidase (GBA) gene mutations in Iranian patients with Gaucher disease.

Authors:  Hadi Mozafari; Mohammad Tghikhani; Zohreh Rahimi; Asad Vaisi Raygani; Shahla Ansari; Shohreh Khatami; Mohammad Reza Alaei; Reza Saghiri
Journal:  Iran J Child Neurol       Date:  2021
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.